Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
for Metastatic Melanoma
18 locations incl. Birmingham
Sponsor: Iovance Biotherapeutics, Inc.
Sex: All·Age: 18 - 70
Code: NCT05727904·Phase 3·Recruiting·Listed Feb 2023